EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Komal L Jhaveri iD, Elgene Lim iD, Rinath Jeselsohn iD, Cynthia X Ma iD, Erika P Hamilton iD, Cynthia Osborne, Manali Bhave, Peter A Kaufman iD, J Thaddeus Beck iD, Luis Manso Sanchez iD, Ritesh Parajuli, Hwei-Chung Wang und 26 weitere

Journal of Clinical Oncology · 10.12.2024 · 42 (35) · 4173-4186

DOI: 10.1200/jco.23.02733 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.12.2024. Verfasst von Komal L Jhaveri und 37 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Everolimus, Benzimidazoles. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1- mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) advanced breast cancer (ABC) and endometrial endometrioid cancer. The ER+/human epidermal growth factor receptor 2–negative (HER2–) ABC experience is reported here. METHODS An i3+3 dose-escalation design was used, followed by dose expansions of imlunestrant as monotherapy or in combination with abemaciclib with or without aromatase inhibitor (AI), everolimus, or alpelisib. Imlunestrant was administered orally once daily and with the combination partner per label. RESULTS Overall, 262 patients with ER+/HER2– ABC were treated (phase Ia, n = 74; phase Ib, n = 188). Among patients who received imlunestrant monotherapy (n = 114), no dose-limiting toxicities or discontinuations occurred. At the RP2D (400 mg once daily), patients (n = 51) reported grade 1-2 nausea (39.2%), fatigue (39.2%), and diarrhea (29.4%). Patients at RP2D had received previous cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; 92.2%), fulvestrant (41.2%), and chemotherapy (29.4%) for ABC and achieved a median progression-free survival (mPFS) of 7.2 months (95% CI, 3.7 to 8.3). Among patients who received imlunestrant + abemaciclib (n = 42) and imlunestrant + abemaciclib + AI (n = 43), most (69.4%) were treatment-naïve for ABC; all were CDK4/6i-naïve. Patients treated with imlunestrant + everolimus (n = 42)/alpelisib (n = 21) had received previous CDK4/6i (100%), fulvestrant (34.9%), and chemotherapy (17.5%) for ABC. No new safety signals or interactions with partnered drugs were observed. The mPFS was 19.2 months (95% CI, 13.8 to not available) for imlunestrant + abemaciclib and was not reached for imlunestrant + abemaciclib + AI. The mPFS with imlunestrant + everolimus/alpelisib was 15.9 months (95% CI, 11.3 to 19.1)/9.2 months (95% CI, 3.7 to 11.1). Antitumor activity was evident regardless of ESR1 mutation status. CONCLUSION Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2– ABC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsEverolimusBenzimidazolesReceptors, EstrogenAminopyridinesErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedAgedAdultAromatase InhibitorsThiazolesAdministration, OralAged, 80 and overProgression-Free SurvivalMolecular Targeted TherapyCyclin-Dependent Kinase 4

Substanzen

EverolimusBenzimidazolesReceptors, EstrogenAminopyridinesErb-b2 Receptor Tyrosine KinasesAromatase InhibitorsThiazolesCyclin-Dependent Kinase 4abemaciclibERBB2 protein, human

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weill Cornell Medical College, New York, NY.
  • Garvan Institute of Medical Research, St Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW, Australia.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Washington University School of Medicine, St Louis, MO.
  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

ORCID-Profile: Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton, Peter A Kaufman, J Thaddeus Beck, Luis Manso Sanchez, Jessica J Tao, Seock-Ah Im, Kathleen Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean-Yves Pierga, Yen-Shen Lu, Timothy Larson, Kostandinos Sideras, Joohyuk Sohn, Sung-Bae Kim, Cristina Saura, Aditya Bardia, Sarah L Sammons, Yujia Li, Bastien Nguyen, Roohi Ismail-Khan, Lillian Smyth

Förderung

  • NCI NIH HHS

Zitieren

APA

Jhaveri, K. L., Lim, E., Jeselsohn, R., Ma, C. X., Hamilton, E. P., Osborne, C., Bhave, M., Kaufman, P. A., Beck, J. T., Manso Sanchez, L., Parajuli, R., Wang, H. C., Tao, J. J., Im, S. A., Harnden, K., Yonemori, K., Dhakal, A., Neven, P., Aftimos, P., …, & Beeram, M. (2024). Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. Journal of Clinical Oncology, 42(35), 4173-4186. https://doi.org/10.1200/jco.23.02733

Vancouver

Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, et al. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. Journal of Clinical Oncology. 2024;42(35):4173-4186. doi:10.1200/jco.23.02733

BibTeX
@article{Jhaveri2024,
  author = {Jhaveri, Komal L and Lim, Elgene and Jeselsohn, Rinath and Ma, Cynthia X and Hamilton, Erika P and Osborne, Cynthia and Bhave, Manali and Kaufman, Peter A and Beck, J Thaddeus and Manso Sanchez, Luis and Parajuli, Ritesh and Wang, Hwei-Chung and Tao, Jessica J and Im, Seock-Ah and Harnden, Kathleen and Yonemori, Kan and Dhakal, Ajay and Neven, Patrick and Aftimos, Philippe and Pierga, Jean-Yves and Lu, Yen-Shen and Larson, Timothy and Jerez, Yolanda and Sideras, Kostandinos and Sohn, Joohyuk and Kim, Sung-Bae and Saura, Cristina and Bardia, Aditya and Sammons, Sarah L and Bacchion, Francesca and Li, Yujia and Yuen, Eunice and Estrem, Shawn T and Rodrik-Outmezguine, Vanessa and Nguyen, Bastien and Ismail-Khan, Roohi and Smyth, Lillian and Beeram, Muralidhar},
  title = {Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {35},
  pages = {4173--4186},
  doi = {10.1200/jco.23.02733}
}
Kostenlos starten →